Caribou Biosciences Inc
NASDAQ:CRBU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Anhui Jinhe Industrial Co Ltd
SZSE:002597
|
CN |
|
Fanuc Corp
OTC:FANUF
|
JP |
|
S
|
Shenzhen SEG Co Ltd
SZSE:000058
|
CN |
|
Precious Dragon Technology Holdings Ltd
HKEX:1861
|
CN |
Caribou Biosciences Inc
EPS (Diluted)
Caribou Biosciences Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Caribou Biosciences Inc
NASDAQ:CRBU
|
EPS (Diluted)
-$1
|
CAGR 3-Years
1%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
Caribou Biosciences Inc
Glance View
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 97 full-time employees. The company went IPO on 2021-07-23. The firm is developing transformative clustered regularly interspaced short palindromic repeats (CRISPR) therapies for patients with devastating diseases. The Company’s CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), enables superior genome-editing precision to develop cell therapies that are specifically engineered for enhanced persistence. The company is advancing a pipeline of allogeneic, or off-the-shelf, chimeric antigen receptor (CAR)-T (CAR-T) and CAR-natural killer (CAR-NK) cell therapies for the treatment of patients with hematologic malignancies and solid tumors. Its lead product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 CAR-T cell therapy with programmed cell death protein 1 (PD-1) removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. The Company’s product candidate also includes CB-011, CB-012 and CB-012.
See Also
What is Caribou Biosciences Inc's EPS (Diluted)?
EPS (Diluted)
-1.6
USD
Based on the financial report for Dec 31, 2025, Caribou Biosciences Inc's EPS (Diluted) amounts to -1.6 USD.
What is Caribou Biosciences Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-22%
Over the last year, the EPS (Diluted) growth was 4%. The average annual EPS (Diluted) growth rates for Caribou Biosciences Inc have been 1% over the past three years , -22% over the past five years .
